SIC 8071 – Medical Laboratories
Valuation | |
---|---|
Market Cap ($M) | 18.93 |
Enterprise Value ($M) | 24.40 |
Book Value ($M) | 22.62 |
Book Value / Share | 3.57 |
Price / Book | 0.84 |
NCAV ($M) | -5.08 |
NCAV / Share | -0.80 |
Price / NCAV | -3.72 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.02 |
Return on Assets (ROA) | 0.01 |
Return on Equity (ROE) | 0.03 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.90 |
Current Ratio | 1.90 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 20.46 |
Assets | 48.16 |
Liabilities | 25.54 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 21.32 |
Operating Income | 2.32 |
Net Income | 0.61 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 5.72 |
Cash from Investing | -6.27 |
Cash from Financing | 1.91 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Stachowiak Raymond C | 21.90 | 6.76 | |
13D/A | Ruffle John F | 6.50 | -25.41 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
12,009 | 46,429 | 25.87 | |
3,185 | 22,614 | 14.08 | |
1,995 | 4,582 | 43.54 | |
2,231 | 15,695 | 14.21 | |
(click for more detail) |
Financial data and stock pages provided by
Fintel.io